IMR Press / FBL / Volume 23 / Issue 11 / DOI: 10.2741/4685

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with Frontiers in Bioscience.


Myeloid heme oxygenase-1: a new therapeutic target in anti-inflammation

Show Less
1 Department of Pediatrics, The Third Xiangya Hospital, Central South University, Changsha, 410006, China
2 Department of Pediatrics, Xiangya Hospital, Central South University, Changsha, 410000, China
3 Department of Surgery, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
4 Research Institute, National Center for Child Health and Development, 2-10-1 Okura, Setagaya-ku, Tokyo 157-8535, Japan
5 National Institute of Infectious Diseases, 1-23-1 Toyama, Shinjuku-ku, Tokyo 162-8640, Japan
Front. Biosci. (Landmark Ed) 2018, 23(11), 2001–2015;
Published: 1 June 2018

An increasing amount of evidence reveals that an orchestrated interplay between myeloid subpopulations in the hematopoietic system plays a significant role in supporting normal functions of the immune system and facilitating homeostatic restoration upon exogenous or endogenous insults. Heme oxygenase-1 (HO-1), a microsomal enzyme discovered decades ago, can metabolize pro-oxidant heme into biliverdin, free iron, and carbon monoxide. This enzymatic reaction produces biological materials, contributing to major immunomodulatory effects. Specifically, HO-1 expression in myeloid cells has been generally acknowledged to drive potent anti-inflammatory and immunosuppressive responses. In this review, the authors focused on elucidating the potential mechanisms underlying myeloid HO-mediated immunomodulation phenotypes, and discussed the potential application of myeloid-specific HO-1 induction as an anti-inflammation therapeutic strategy.

Heme Oxygenase-1
Back to top